Anna Eisert

540 total citations
11 papers, 10 citations indexed

About

Anna Eisert is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Anna Eisert has authored 11 papers receiving a total of 10 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Anna Eisert's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (4 papers) and Fibroblast Growth Factor Research (3 papers). Anna Eisert is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (4 papers) and Fibroblast Growth Factor Research (3 papers). Anna Eisert collaborates with scholars based in Germany, France and United Kingdom. Anna Eisert's co-authors include Sebastian Michels, Sabine Merkelbach‐Bruse, María González‐Cao, Colin R. Lindsay, Roman K. Thomas, Anne M. Schultheis, Katharina König, Elke Binot, Sophia Koleczko and Ullrich Graeven and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and JCO Precision Oncology.

In The Last Decade

Anna Eisert

8 papers receiving 10 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Eisert Germany	2	10	6	5	4	1	11	10
Yon Ho Jee United States	3	11 1.1×	5 0.8×	6 1.2×	4 1.0×		6	22
Andreas Schlesinger Germany	2	8 0.8×	6 1.0×	5 1.0×	3 0.8×		4	12
X. L. Guo China	2	12 1.2×	6 1.0×	5 1.0×	6 1.5×		7	20
Tifenn L’Haridon France	2	8 0.8×	5 0.8×	5 1.0×	6 1.5×		3	11
Maialen Barrero Spain	3	7 0.7×	4 0.7×	8 1.6×	5 1.3×		5	14
Haohui Fang China	2	9 0.9×	8 1.3×	4 0.8×	8 2.0×		3	15
Diana Merino Vega United States	4	6 0.6×	8 1.3×	8 1.6×	4 1.0×		8	16
Ameet Guria United States	2	8 0.8×	9 1.5×	9 1.8×	3 0.8×		3	16
David Bourque United States	3	8 0.8×	9 1.5×	9 1.8×	3 0.8×		5	18
Pablo Sáez Scherbovsky Argentina	2	13 1.3×	4 0.7×	5 1.0×	5 1.3×		4	22

Countries citing papers authored by Anna Eisert

Since Specialization

Citations

This map shows the geographic impact of Anna Eisert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Eisert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Eisert more than expected).

Fields of papers citing papers by Anna Eisert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Eisert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Eisert. The network helps show where Anna Eisert may publish in the future.

Co-authorship network of co-authors of Anna Eisert

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Eisert. A scholar is included among the top collaborators of Anna Eisert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Eisert. Anna Eisert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Riedel, Richard, Lucia Nogová, Sebastian Michels, et al.. (2025). MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition. JTO Clinical and Research Reports. 7(3). 100925–100925.

Aldea, Mihaela, I. Monnet, Sophie Cousin, et al.. (2024). Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). 8647–8647. 1 indexed citations

Fassunke, Jana, Michael Püsken, Elke Binot, et al.. (2023). Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report. JCO Precision Oncology. 7(7). e2200467–e2200467. 2 indexed citations

Le, Xiuning, Anna Eisert, Te‐Chun Hsia, et al.. (2023). Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.. Journal of Clinical Oncology. 41(16_suppl). 9070–9070.

Siemanowski, Janna, Florian Malchers, Matthias Scheffler, et al.. (2023). Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.. Journal of Clinical Oncology. 41(16_suppl). e21139–e21139. 1 indexed citations

Kron, Anna, Sebastian Michels, Lucia Nogová, et al.. (2022). 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Annals of Oncology. 33. S1006–S1006. 1 indexed citations

Levetzow, Cornelia von, Sebastian Michels, Lucia Nogová, et al.. (2022). 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Annals of Oncology. 33. S56–S57. 1 indexed citations

Malchers, Florian, Axel M. Hillmer, Sabine Merkelbach‐Bruse, et al.. (2022). Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.. Journal of Clinical Oncology. 40(16_suppl). e21013–e21013.

Scheffler, Matthias, Michaela A. Ihle, Rebecca Hein, et al.. (2016). Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.. Journal of Clinical Oncology. 34(15_suppl). 9018–9018. 2 indexed citations

10.

Frank, Rieke, Matthias Scheffler, Sebastian Michels, et al.. (2015). KEAP1-mutations in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). 8097–8097. 1 indexed citations

11.

Eisert, Anna, Matthias Scheffler, Sebastian Michels, et al.. (2014). Genetic Variability and Clinical Presentation of Patients with Non-Small Cell Lung Cancer (Nsclc) Harboring Met-Amplifications. Annals of Oncology. 25. iv463–iv463. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact